Guardant Health Inc GH Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

100

Price:

$98.00
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

14,900

Price:

$96.83
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$95.50
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$94.00
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

26,394

Price:

$93.04
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

3,106

Price:

$92.23
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Talasaz AmirAli

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

100

Price:

$98.00
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Talasaz AmirAli

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

14,900

Price:

$96.83
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Talasaz AmirAli

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$95.50
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Talasaz AmirAli

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$94.00

Filings by filing date

Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

100

Price:

$98.00
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

14,900

Price:

$96.83
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$95.50
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$94.00
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

26,394

Price:

$93.04
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

3,106

Price:

$92.23
Nov 19, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

12,409

Price:

$98.75
Nov 19, 2021 (filed on Nov 23, 2021)

Insider Name:

Eltoukhy Helmy

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

37,591

Price:

$97.90
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Talasaz AmirAli

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

100

Price:

$98.00
Nov 23, 2021 (filed on Nov 23, 2021)

Insider Name:

Talasaz AmirAli

Ownership Type:

Direct Ownership

Securities:

COMMON STOCK

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

14,900

Price:

$96.83

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	505 Penobscot Dr REDWOOD CITY CA 94063-4737
Tel:	1-415-9375405
Website:	www.guardanthealth.com
IR:	See website

Key People

Helmy A. Eltoukhy Chairman of the Board, Co-Chief Executive Officer	Amirali Talasaz President, Co-Chief Executive Officer, Director	Michael Bell Chief Financial Officer
John Gomes Saia Senior Vice President, General Counsel, Corporate Secretary	Craig Eagle Chief Medical Officer	Michael J. Wiley Head of Corporate Affairs

Business Overview

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood-based tests, data sets and advanced analytics. It has developed its Guardant360, Guardant360 CDx and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. It also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need in Stage II-III colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor Deoxyribonucleic Acid (DNA) in blood. The Company's tests are used by biopharmaceutical companies for a range of applications, including identifying target patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic development.

Financial Overview

For the nine months ended 30 September 2021,Guardant Health Inc revenues increased 27% to $265.5M. Netloss increased 97% to $314.8M. Revenues reflect UnitedStates segment increase of 31% to $250.6M. Higher net lossreflects Research and development expense increase of 73%to $176.9M (expense), Sales and marketing expense increaseof 77% to $122M (expense).

Employees:	864 as of Dec 31, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$9,345M as of Sep 30, 2021
Annual revenue (TTM):	$343.86M as of Sep 30, 2021
EBITDA (TTM):	-$381.18M as of Sep 30, 2021
Net annual income (TTM):	-$408.50M as of Sep 30, 2021
Free cash flow (TTM):	-$248.94M as of Sep 30, 2021
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	101,656,348 as of Oct 31, 2021
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Guardant Health Inc (OQ:GH)